ZANVASTRO
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- ZANVASTRO
- Generic name
- ZILGANERSEN
- Manufacturer
- Ionis Pharmaceuticals Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- af6ca330-46d3-4ed6-b2af-bd6db3133fd1
- SPL ID
- 5b752db5-061f-8804-e063-6394a90aa4af
- Version
- 3
- Effective date
- 2026-09-14
- Source export date
- 2026-11-13
- Source partition
- 6
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:19:53
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 220210 | derived:openfda.application_number |
| application number | NDA220210 | openfda.application_number | |
| brand name | ZANVASTRO | openfda.brand_name | |
| generic name | ZILGANERSEN | openfda.generic_name | |
| manufacturer name | Ionis Pharmaceuticals Inc. | openfda.manufacturer_name | |
| ndc | package | 71860-200-01 | openfda.package_ndc |
| ndc | package | 71860-304-01 | openfda.package_ndc |
| ndc | package | 71860-104-01 | openfda.package_ndc |
| ndc | product | 71860-304 | openfda.product_ndc |
| ndc11 | package | 71860030401 | derived:openfda.package_ndc |
| ndc11 | package | 71860020001 | derived:openfda.package_ndc |
| ndc11 | package | 71860010401 | derived:openfda.package_ndc |
| rxcui | 2753034 | openfda.rxcui | |
| rxcui | 2753040 | openfda.rxcui | |
| spl id | 5b752db5-061f-8804-e063-6394a90aa4af | id | |
| spl set id | af6ca330-46d3-4ed6-b2af-bd6db3133fd1 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS 5.1 Aseptic Meningitis If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care. Adverse reactions of aseptic meningitis (also called chemical meningitis or drug-induced aseptic meningitis) were reported in patients treated with ZANVASTRO during the double-blind and open-label periods of Study 1. One patient experienced a serious adverse reaction of aseptic meningitis during the double-blind treatment period of Study 1, which reoccurred in the open-label extension period and required dose interruption and pretreatment with intravenous dexamethasone prior to subsequent administration of ZANVASTRO. Despite corticosteroid premedication, CSF white blood cell (WBC) and protein increased with continued exposure but the patient remained asymptomatic and did not require discontinuation from treatment. In addition, nonserious adverse drug reactions of CSF WBC increased have also been reported with ZANVASTRO [see Adverse Reactions ( 6.1 )] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Aseptic Meningitis [see Warnings and Precautions ( 5.1 )] Most common adverse reactions (incidence >25% patients treated with ZANVASTRO and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ionis Pharmaceuticals, Inc. at 1-833-644-6647 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ZANVASTRO was evaluated in 53 pediatric and adult patients with Alexander disease in Study 1 [see Clinical Studies ( 14 )] . Thirty-eight patients received ZANVASTRO for 1 year, and 18 patients received ZANVASTRO for 2 years. The median exposure was 60 weeks in all groups. The most common adverse reactions during the Double-Blind Treatment Period (incidence >25% of patients treated with ZANVASTRO 50 mg and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Table 3 includes the common adverse reactions that occurred in ≥10% of patients treated with ZANVASTRO and 10% greater than control. Table 3. Adverse Reactions in Patients with Alexander Disease that Occurred in ≥10% of Patients Treated with ZANVASTRO and 10% Greater than Control Adverse Reaction ZANVASTRO 50 mg (N=24) % Control (N=17) % Vomiting 50 29 Back pain 50 18 Cough 38 18 Headache 29 12 Post lumbar puncture syndrome 29 6 Arthralgia 25 6 Oropharyngeal pain 21 0 Dysphagia 17 6 Patients Less Than 2 Years of Age The adverse reactions of patients less than 2 years of age are expected to be similar to that of pediatric patients 2 years of age and older. Increased White Blood Cell Count in the CSF Pleocytosis (or increased white blood cell count in CSF) was observed in 7 (29%) patients treated with ZANVASTRO 50 mg following the administration of the first 2 to 4 doses, compared to 3 (18%) patients in the control group in the double-blind treatment period of the Main Study, and in an additional 6 patients treated with ZANVASTRO in the open-label extension period [see Warnings and Precautions ( 5.1 )] .
adverse reactions
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ZANVASTRO was evaluated in 53 pediatric and adult patients with Alexander disease in Study 1 [see Clinical Studies ( 14 )] . Thirty-eight patients received ZANVASTRO for 1 year, and 18 patients received ZANVASTRO for 2 years. The median exposure was 60 weeks in all groups. The most common adverse reactions during the Double-Blind Treatment Period (incidence >25% of patients treated with ZANVASTRO 50 mg and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Table 3 includes the common adverse reactions that occurred in ≥10% of patients treated with ZANVASTRO and 10% greater than control. Table 3. Adverse Reactions in Patients with Alexander Disease that Occurred in ≥10% of Patients Treated with ZANVASTRO and 10% Greater than Control Adverse Reaction ZANVASTRO 50 mg (N=24) % Control (N=17) % Vomiting 50 29 Back pain 50 18 Cough 38 18 Headache 29 12 Post lumbar puncture syndrome 29 6 Arthralgia 25 6 Oropharyngeal pain 21 0 Dysphagia 17 6 Patients Less Than 2 Years of Age The adverse reactions of patients less than 2 years of age are expected to be similar to that of pediatric patients 2 years of age and older. Increased White Blood Cell Count in the CSF Pleocytosis (or increased white blood cell count in CSF) was observed in 7 (29%) patients treated with ZANVASTRO 50 mg following the administration of the first 2 to 4 doses, compared to 3 (18%) patients in the control group in the double-blind treatment period of the Main Study, and in an additional 6 patients treated with ZANVASTRO in the open-label extension period [see Warnings and Precautions ( 5.1 )] .
adverse reactions table
<table width="50%" cellspacing="0" cellpadding="0"> <caption>Table 3. Adverse Reactions in Patients with Alexander Disease that Occurred in ≥10% of Patients Treated with ZANVASTRO and 10% Greater than Control</caption> <col width="33.33%" align="left" valign="middle"/> <col width="33.33%" align="left" valign="middle"/> <col width="33.33%" align="left" valign="middle"/> <thead> <tr styleCode="First Last"> <td rowspan="2" align="left" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Adverse Reaction</content> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">ZANVASTRO 50 mg (N=24) % </content> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Control (N=17) % </content> </td> </tr> </thead> <tfoot> <tr styleCode="First Last"> <td colspan="3" align="left" styleCode="Lrule Rrule Toprule Botrule"/> </tr> </tfoot> <tbody> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Vomiting</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>50</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Back pain</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>50</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>18</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Cough</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>38</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>18</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Headache</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>12</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Post lumbar puncture syndrome</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Arthralgia</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>25</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Oropharyngeal pain</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>21</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>0</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Dysphagia</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>17</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="50%" cellspacing="0" cellpadding="0"> <caption>Table 3. Adverse Reactions in Patients with Alexander Disease that Occurred in ≥10% of Patients Treated with ZANVASTRO and 10% Greater than Control</caption> <col width="33.33%" align="left" valign="middle"/> <col width="33.33%" align="left" valign="middle"/> <col width="33.33%" align="left" valign="middle"/> <thead> <tr styleCode="First Last"> <td rowspan="2" align="left" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Adverse Reaction</content> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">ZANVASTRO 50 mg (N=24) % </content> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <content styleCode="bold">Control (N=17) % </content> </td> </tr> </thead> <tfoot> <tr styleCode="First Last"> <td colspan="3" align="left" styleCode="Lrule Rrule Toprule Botrule"/> </tr> </tfoot> <tbody> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Vomiting</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>50</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Back pain</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>50</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>18</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Cough</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>38</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>18</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Headache</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>12</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Post lumbar puncture syndrome</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>29</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Arthralgia</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>25</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Oropharyngeal pain</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>21</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>0</paragraph> </td> </tr> <tr> <td align="left" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>Dysphagia</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>17</paragraph> </td> <td align="center" styleCode="Lrule Rrule Toprule Botrule"> <paragraph>6</paragraph> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.